IMBRUVICA Prescribing Information for WM Includes iNNOVATE Data
In late December 2020, biopharmaceutical company AbbVie announced via press release that the prescribing information for IMBRUVICA (ibrutinib) is now updated to include long-term
In late December 2020, biopharmaceutical company AbbVie announced via press release that the prescribing information for IMBRUVICA (ibrutinib) is now updated to include long-term
On January 10, 2021, biotechnology company BioMarin Pharmaceutical Inc. (“BioMarin”) shared positive data from its Phase 3 GENEr8-1 clinical trial. The clinical trial is
In a recent press release from mid-January 2020, the Pulmonary Fibrosis Foundation (PFF) announced that its registry, the PFF Registry, was being sponsored by
According to an article in BioSpace, Dyne Therapeutics has recently announced data from preclinical trials of its FORCE platform. This program is aimed at creating
In an exciting press release, gene therapy platform company Lysogene announced that it had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA)
According to a story from GlobeNewswire, a new partnership between the precision genetic medicine company Akouos, Inc. and and Blueprint Genetics has produced the Resonate
SIGN UP FOR OUR NEWSLETTER | |
|
© Copyright Patient Worthy
Join PW
We’ve heard your feedback. Now, by creating a login below, you can customize your homepage to the rare conditions that are most important to you. You can also share your rare story directly through the site, so being part of our community is easier than ever!